Want to see ABEO full AI Analyst Report?
ABEO Stock Chart & Stats
$5.50
-$0.15(-2.50%)
At close: 4:00 PM EST
$5.50
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$4.00 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)1.33M
Market Cap
$402.39M
Enterprise Value$108.56
Total Cash (Recent Filing)$168.27M
Total Debt (Recent Filing)$23.17M
Price to Earnings (P/E)5.7
Beta1.54
Next Earnings
Aug 12, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume1,511,643
30 Day Avg. Volume1,331,427
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.75Price Target Upside259.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$66.29M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Rebound & Gross MarginA rapid revenue rebound to $8.7M with a ~52% gross margin signals initial commercial product-market fit and the start of a durable revenue base. Sustained margin levels support scalable gross profitability as volumes grow, enabling operating leverage if SG&A and R&D normalize over time.
Broad Payer CoverageEstablished coverage for 95% of commercially insured lives materially reduces long-term reimbursement risk for new patients. Durable payer acceptance improves revenue visibility and supports steady uptake across centers, reducing reliance on ad-hoc approvals for sizable portions of the target population.
Pipeline Advancement — ABO-701 Pre-IND ProgressConstructive FDA engagement and a targeted IND timeline for ABO-701 create a defined near‑to‑medium term development milestone ladder. A progressing oncology asset diversifies long-term value drivers and offers multiple partnership or royalty outcomes post-Phase I.
Bears Say
High Cash Burn & Negative Operating Cash FlowPersistent large negative operating and free cash flow requires ongoing external financing and constrains strategic optionality. Continued cash burn pressures runway, limits ability to scale centers quickly, and raises dilution or covenant risks that can materially affect long-term capital allocation.
Earnings Quality DisconnectReported positive net income despite deep operating losses indicates reliance on non-operational items or one-offs. This undermines confidence that profitability is sustainable and increases the risk of earnings volatility as accounting benefits reverse or cash generation fails to align with reported earnings.
Elevated SG&A And Scaling ComplexityMaterial SG&A growth increases fixed cost burden and slows path to operating leverage. Combined with long, variable QTC activation and biopsy lead times, the company faces persistent margin pressure and unpredictable revenue ramping, complicating durable profitability even as demand exists.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics Inc’s price range in the past 12 months?
Abeona Therapeutics Inc lowest stock price was $4.00 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics Inc’s market cap?
Abeona Therapeutics Inc’s market cap is $402.39M.
When is Abeona Therapeutics Inc’s upcoming earnings report date?
Abeona Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were Abeona Therapeutics Inc’s earnings last quarter?
Abeona Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.035.
Is Abeona Therapeutics Inc overvalued?
According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued.
Does Abeona Therapeutics Inc pay dividends?
Abeona Therapeutics Inc does not currently pay dividends.
What is Abeona Therapeutics Inc’s EPS estimate?
Abeona Therapeutics Inc’s EPS estimate is -0.23.
How many shares outstanding does Abeona Therapeutics Inc have?
Abeona Therapeutics Inc has 56,995,144 shares outstanding.
What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?
Abeona Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went up 0.528%.
Which hedge fund is a major shareholder of Abeona Therapeutics Inc?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (259.09% Upside)
$19.75 (259.09% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 40.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.52%
12-Months-Change
Fundamentals
Return on Equity
41.40%
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO Stock 12 Month Forecast
Average Price Target
$19.75
▲(259.09% Upside)
Technical Analysis
Ownership Overview
6.31% Insiders
6.74% Mutual Funds
0.03% Other Institutional Investors
77.59% Public Companies and
Individual Investors